| DC49523 |
27-Methyl withaferin A |
27-Methyl withaferin A (comppund 26) is an apoptosis inducer with anticancer effects. 27-Methyl withaferin A shows antiproliferative effects against HeLa, A-549 and MCF-7 human tumor cell lines with IC50 values of 3.2 μM, 4.2 μM and 1.4 μM, respectively. |
|
| DC49524 |
Petromurin C |
Petromurin C is a bisindolylbenzenoid compound isolated from the ascostromata of Petromycesmuricatus. Petromurin C induces protective autophagy and apoptosis in FLT3-ITD-positive AML. |
|
| DC49525 |
hGGPPS-IN-2 |
hGGPPS-IN-2 (Compound 16g) is a potent inhibitor of the human geranylgeranyl pyrophosphate synthase (hGGPPS). hGGPPS-IN-2 is an analogue of C-2-substituted thienopyrimidine-based bisphosphonates (C2-ThP-BPs). hGGPPS-IN-2 induces target-selective apoptosis of multiple myeloma (MM) cells and exhibits antimyeloma activity in vivo. |
|
| DC49526 |
Physalin A |
Physalin A is a withanolide isolated from Physalis alkekengi var. franchetii. Physalin A induces apoptosis associated with up-regulation of caspase-3 and caspase-8 expression. Physalin A induces autophagy, found to antagonize apoptosis in HT1080 cells. Physalin A has the potential for the research of cancer disease. |
|
| DC49527 |
Autophagy inducer 2 |
Autophagy inducer 2 (Compound 11i) is a potent autophagy inducer. Autophagy inducer 2 exhibits apparent antiproliferative activity against the MCF-7 cell line with an IC50 value of 1.31 μM and remarkably inhibits the colony formation of the MCF-7 cells. Autophagy inducer 2 arrests the MCF-7 cells in the G2/M phase by regulating the cell-cycle-related proteins Cdk-1 and Cyclin B1. Autophagy inducer 2 has the potential for the research of breast cancer. |
|
| DC49528 |
Anticancer agent 39 |
Anticancer agent 39 (compound B12), a fluorescent derivative of Jiyuan Oridonin A (JOA), induces the collapse of mitochondrial membrane potential (MMP)and thus induced apoptosis.Anticancer agent 39 inhibits cell cloning and migration.Anticancer agent 39 exhibits promising anti-proliferative activity against HGC-27 cells with IC50 value of 0.39 μM. |
|
| DC49529 |
NCX4040 |
NCX4040 (NO-Aspirin), a non-steroidal anti-inflammatory drug (NSAID), is a nitric oxide (NO) releasing form of Aspirin. NCX4040 induces apoptosis in PC3 metastatic prostate cancer cells. NCX4040 has anti-inflammatory and anti-cancer effects. |
|
| DC49530 |
Tricetin |
Tricetin is a potent competitive inhibitor of the Keap1-Nrf2 Protein Protein Interaction (PPI). Tricetin significantly improves cell viability and suppresses mitochondria-mediated apoptosis. Tricetin also induced the protein expression of Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and its transcriptional activation, resulting in the up-regulated expression of heme oxygenase-1 (HO-1), which conferred neuroprotection against 6-OHDA-induced oxidative damage. Tricetin has the potential for the research of Parkinson's disease (PD). |
|
| DC49531 |
hGGPPS-IN-3 |
hGGPPS-IN-3 (Compound 13h) is a potent inhibitor of the human geranylgeranyl pyrophosphate synthase (hGGPPS). hGGPPS-IN-3 is an analogue of C-2-substituted thienopyrimidine-based bisphosphonates (C2-ThP-BPs). hGGPPS-IN-3 induces target-selective apoptosis of multiple myeloma (MM) cells and exhibits antimyeloma activity in vivo. |
|
| DC49532 |
IM-93 |
IM-93 inhibits ferroptosis and NETosis with an IC< sub>50 of 0.45 µM for cell death inhibition. |
|
| DC49533 |
ADH-6 |
ADH-6 is a tripyridylamide compound. ADH-6 abrogates self-assembly of the aggregation-nucleating subdomain of mutant p53 DBD. ADH-6 targets and dissociates mutant p53 aggregates in human cancer cells, which restores p53's transcriptional activity, leading to cell cycle arrest and apoptosis. ADH-6 has the potential for the research of cancer diseases. |
|
| DC49534 |
RIPK1-IN-12 |
RIPK1-IN-12 is a potent RIPK1 inhibitor. RIPK1-IN-12 inhibits necroptosis in both human and mouse cells, with EC50 values of 1.6 and 2.9 nM, respectively. |
|
| DC49535 |
RIPK1-IN-11 |
RIPK1-IN-11 is a potent and orally active RIPK1 inhibitor (Kd=9.2 nM; IC50=67 nM). RIPK1-IN-11 inhibits necroptosis in both human and mouse cells (EC50=17-30 nM). Anti-inflammatory activity. |
|
| DC49536 |
RIPK1-IN-10 |
RIPK1-IN-10 is a potent RIPK1 inhibitor, example 37, extracted from patent WO2021160109. |
|
| DC49537 |
ISIS 104838 |
ISIS 104838 is an antisense oligonucleotide drug that reduces the production of tumor necrosis factor (TNF-alpha), a substance that contributes to joint pain and swelling in rheumatoid arthritis. |
|
| DC50162 |
Bcl-2/Mcl-1-IN-3 |
Bcl-2/Mcl-1-IN-3 (compound 1) is a Bcl-2/Mcl-1 inhibitor, with Kis of 0.14 μM and 0.23 μM for Mcl-1 and Bcl-2, respectively. Bcl-2/Mcl-1-IN-3 can be used for the research of cancer. |
|
| DC50163 |
Mcl-1 inhibitor 7 |
Mcl-1 inhibitor 7 is a potent Mcl-1 inhibitor, example 35, extracted from patent WO2020097577A. |
|
| DC50164 |
Bcl-2/Mcl-1-IN-2 |
Bcl-2/Mcl-1-IN-2 (compound 2) is a Bcl-2/Mcl-1 inhibitor, with Kis of 0.88 μM and 4.70 μM for Mcl-1 and Bcl-2, respectively. Bcl-2/Mcl-1-IN-2 can be used for the research of cancer. |
|
| DC50165 |
Bcl-2/Mcl-1-IN-1 |
Bcl-2/Mcl-1-IN-1 (compound 3) is a Bcl-2/Mcl-1 inhibitor, with Kis of 1.19 μM and 4.53 μM for Mcl-1 and Bcl-2, respectively. Bcl-2/Mcl-1-IN-1 can be used for the research of cancer. |
|
| DC50166 |
Bim-IN-1
Featured
|
Bim-IN-1 is a potent Bim expression inhibitor. Bim-IN-1 reduces Bim expression levels and has little inhibitory effect upon protein kinase A activity and minimal toxicity. |
|
| DC50250 |
PK9327 |
PK9327 is a small-molecule stabilizer targeting cavity-creating p53 cancer mutations. |
|
| DC50251 |
Mutant p53 modulator-1 |
Mutant p53 modulator-1 is a mutant p53 modulator. Mutant p53 modulator-1 reduces the progression of cancers that contain a p53 mutation (extracted from patent WO2021231474A1, compound 231B). |
|
| DC50252 |
NSC405640 |
NSC405640 is a potent inhibitor of the MDM2-p53 interaction. NSC405640 rescues structural p53 mutations. NSC405640 selectively inhibits the growth of cell lines with wild-type p53. |
|
| DC70067 |
NSC194598 |
NSC194598 is a specific small molecule inhibitor that inhibits p53 sequence-specific DNA binding in vitro (IC50=180 nM) and in vivo. |
|
| DC70122 |
BTC-8 |
A derivative of BAM-7 that acts as a nove potent, direct activator of Bax with EC50 of 700 nM; inhibits GBM cell proliferation, arrests the cell cycle, and induces apoptosis through the induction of mitochondrial membrane permeabilization; also blocks proliferation and self-renewal of GSCs and induces their apoptosis; sensitizes both GBM cells and GSCs to the alkylating agent Temozolomide. |
|
| DC70131 |
DIMP53-1 |
A novel small-molecule dual inhibitor of p53-MDM2/X interactions by potentially binding to p53, without effect on other MDM; causes growth inhibition, mediated by p53 stabilization and upregulation of p53 transcriptional targets involved in cell cycle arrest and apoptosis; shows a p53-dependent antitumor activity in human tumor xenograft mice models; a novel p53 activator. |
|
| DC70186 |
ALRN-6924 |
ALRN-6924 (ALRN6924) is a potent dual inhibitor of MDM2/MDMX.ALRN-6924 demonstrated potent anti-proliferative activity in a dose-dependent manner in two ER+ cell lines with WT TP53, MCF-7 and ZR-75-1, with IC50 values of 113 nM and 500 nM respectively.The combination of ALRN-6924 and chemotherapeutic agents synergistically inhibit cell proliferation in vitro, ALRN-6924 combined with paclitaxel reactivates p53 and induces cell cycle arrest and apoptosis in vitro.ALRN-6924 mutually enhances both paclitaxel and eribulin antitumor efficacy and inhibits tumor growth in vivo. |
|
| DC70246 |
BFL-1 inhibitor 4E14
Featured
|
BFL-1 inhibitor 4E14 (4E14) is a potent, selective, covalent BFL-1 inhibitor that disrupt BH3-binding activity with IC50 of 1.3 uM, targets a unique C55 residue in the BFL-1 groove.4E14 blocks BFL-1 suppression of BAX-mediated mitochondrial apoptosis. |
|
| DC70294 |
CCT369347 |
CCT369347 (CCT-369347) is potent selective inhibitor of BCL-6 with TR-FRET IC50 of 26 nM.CCT369347 demonstrated antiproliferative activity in a panel of BCL6-positive lymphoma cell lines (OCI-Ly1, SU-DHL-4, and SU-DHL-6) with IC50 of 1.68-3.45 uM, with weaker activity against low BCL6 expression cells and noncytotoxocity. CCT369347 inhibits BCL6 in a cellular assay with a submicromolar IC50 and shows promising early PK. |
|
| DC70365 |
D-NA-NOXA SAHB-15 R31E |
D-NA-NOXA SAHB-15 R31E is a peptidic, functionally selective and cell-permeable BFL-1/A1 inhibitor that is specifically cytotoxic to BFL-1/A1-dependent human cancer cells. |
|
